- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00197522
Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2
October 31, 2012 updated by: Hamilton Health Sciences Corporation
A Phase I Study Investigating Multiple Injections of Autologous CD34+ Derived Dendritic Cells Transduced With an Adenovirus Vector Expressing Inactivated HER-2/Neu in Patients With Metastatic Breast Cancer
We, the researchers at Hamilton Health Sciences, have developed a novel approach to cancer therapy using transfected dendritic cells (DCs) to generate enhanced immunity to defined tumor antigens.
Dendritic cells are highly specialized antigen presenting cells found in the bone marrow, lymph nodes, skin and thymus.
Infection of DCs with Adenovirus (Ad) vectors incorporating genes for defined tumor antigens enables intracellular expression and major histocompatability complex (MHC)-restricted presentation of tumor peptides by transfected DCs.
Given the potent immunostimulatory properties of DCs and ability to use gene transfer to "load" DCs with tumor antigen, we hypothesize that administration of transduced autologous DCs may have potential therapeutic benefit as a cancer vaccine.
We have examined Ad-tumor antigen DC based vaccination in murine models of breast cancer and melanoma.
In both models, injection(s) of Ad-transduced DCs results in highly potent immune activation and antigen-specific anti-tumor responses.
In these models, high levels of antigen-specific, cytotoxic effector lymphocytes that recognize and kill cancer cells directly correlates with a therapeutic response (tumor regression and/or complete protection of animals subsequently re-challenged with tumor cells).
Animals demonstrating specific in vitro immunity are protected against subsequent injection of cancer cells.
Moreover, we have observed complete resolution and significant long-term survival in animals with established metastatic disease with no demonstrable toxicity.
As opposed to vaccination protocols with tumor peptides or purified epitopes that are MHC-I restricted (i.e.
HLA-A2), we have found that injection of DCs transduced with a vector expressing the entire tumor antigen results in peptide presentation from both MHC-I and MHC-II complexes.
The subsequent immune response is comprised of both CD4+ and CD8+ T cell populations.
Thus, Ad-based gene transfer of tumor antigens appears to be an efficient approach: (1) enabling sustained endogenous peptide processing, and (2) facilitating DC-specific presentation to the host immune system.
We have shown that using a replication deficient adenovirus vector expressing Her-2/neu DNA under the control of a human mouse mammary tumor virus (MMTV) promoter that we can transfect bone marrow derived DCs (AdHer2/DC).
These cells are then used to immunize recipient mice against tumour challenge with Her2 transgenic tumour cells.
The protection is antigen specific (anti Her2).
On the basis of these pre-clinical studies we will initiate a pilot trial of the AdHer2/DC vaccine in Her -2/neu overexpressing patients with metastatic breast cancer.
Long-term goals and implications of possible results: The goals of this initial pilot phase I study are to evaluate the safety and dosing schedule of the vaccine therapy.
The vaccine will be tested in subsequent phase II and III studies to determine efficacy in comparison to standard therapies.
The long-term goals are to eventually test this therapy in the adjuvant breast cancer setting in Her-2/neu overexpressing patients.
Study Overview
Detailed Description
Following written, informed consent, consecutive cohorts of 3-6 patients, up to a maximum of 18 patients, will be treated at increasing dose levels based on a modified Fibonacci scheme.
Peripheral blood progenitor cells will be obtained from each patient following cytokine mobilization (with GM-CSF and G-CSF).
Selected CD34+ cells are then cultured with human GM-CSF, human TNFα, Flt-3 ligand and human interleukin-4.
The CD34+ derived dendritic cells are then transduced with an adenovirus expressing rat HER2/neu.
These transduced DCs are then injected intradermally into the patient.
Patients will be injected with the AdHER2/neu transduced DCs every 21 days for a total of three treatment cycles.
The starting dose of dendritic cells will be 10 X 10^6 DCs.
If none of the initial three patients treated at this dose experiences dose limiting toxicity (DLT) then a new cohort of three patients will be treated at a second dose level of 50 X 10^6 DCs.
If any patient experiences DLT then up to six patients will be treated at the current dose level; if 2/6 or fewer patients experience DLT, we will escalate to the to the second dose level.
If 3 or more patients experience DLT, the maximum tolerated dose will be deemed as exceeded and a second cohort of 3 patients will be treated at a 10 fold dose reduction of the initial dose level.
The third dose level will consist of 100 x 10^6 DCs.
All treatments will occur in the out-patient setting and patients will be seen prior to each injection and then monthly for at least three months following the last injection of AdHER2/neu DCs.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, M8V 1C3
- Hamilton Health Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 80 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
Patients with metastatic breast cancer who are HER2/neu positive (3+ by immunohistochemistry or FISH positive) and either
- currently receiving hormonal therapy or are candidates for such or
- being considered for trastuzumab or
- their cancer has progressed on trastuzumab
Exclusion Criteria:
Patients are excluded from the study if they meet any one of the following criteria:
- Age less than 16 years.
- Pregnant or lactating female.
- Previous malignancy other than non-melanoma skin cancer.
- More than three prior courses of cytotoxic chemotherapy for metastatic disease.
- Concurrent use of chemotherapy, immunotherapy, or gene therapy. Concurrent hormonal therapy (tamoxifen, aromatase inhibitors or exemestane) is permitted.
- Treatment with trastuzumab within 16 weeks prior to first dose of vaccine therapy.
- Documented central nervous system metastases.
- Patients with any an acute illness that would interfere with the mobilization of stem cells or the administration of vaccination cellular therapy (ie. unstable angina, renal or liver failure, or severe chronic obstructive airways disease) are ineligible.
- Any patients requiring concurrent immunosuppressive therapy (eg. corticosteroids)
- Patients with a life expectancy of less than six months.
- ECOG performance status of >2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine the maximum tolerated dose (MTD) and/or the maximum attainable dose (MAD) of a vaccine consisting of human autologous CD34+ DCs transduced by AdHER-2.1
|
To evaluate toxicity
|
Secondary Outcome Measures
Outcome Measure |
---|
To detect evidence of clinical efficacy as measured by objective tumor reduction
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Levine Mark, MD, Hamilton Health Sciences Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Primary Completion (Actual)
May 1, 2012
Study Completion (Actual)
May 1, 2012
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 20, 2005
Study Record Updates
Last Update Posted (Estimate)
November 1, 2012
Last Update Submitted That Met QC Criteria
October 31, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- file#9427-HO778-34C
- CBCRA
- Award # 2003HOO542
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCActive, not recruitingBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedMale Breast Cancer | Breast - FemaleUnited States
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastJapan
Clinical Trials on CD34+ derived DCs
-
IRCCS San RaffaeleSuspended
-
Tongji HospitalKousai Bio Co., Ltd.Enrolling by invitationEBV-associated Haematologic NeoplasmsChina
-
Kousai Bio Co., Ltd.Kousai Bio Co., Ltd.Active, not recruitingEBV-associated LymphomasChina
-
Genzyme, a Sanofi CompanyCompletedCarcinoma, Renal CellUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingMDS (Myelodysplastic Syndrome) | Severe Aplastic AnemiaUnited States
-
Minovia Therapeutics Ltd.RecruitingMitochondrial Diseases | Pearson SyndromeIsrael
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Not yet recruitingEpilepsy | Working MemoryUnited States
-
Queen Mary University of LondonBarts & The London NHS TrustCompletedTraumatic Brain Injury | Intracranial HypertensionUnited Kingdom
-
University of FloridaImmunomic Therapeutics, Inc.Terminated
-
University Hospital Inselspital, BerneActive, not recruiting